Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

690941.pdf (369.53 KB)

Document type

Article

Version

Accepted version

Publication date

2019

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/141878

A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.ejmech.2019.07.051

Abstract

The development of multitarget compounds against multifactorial diseases, such as Alzheimer's disease, is an area of very intensive research, due to the expected superior therapeutic efficacy that should arise from the simultaneous modulation of several key targets of the complex pathological network. Here we describe the synthesis and multitarget biological profiling of a new class of compounds designed by molecular hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different linker lengths and linkage positions, to preserve or not the memantine-like polycyclic unsubstituted primary amine. The best hybrids exhibit greater potencies than parent compounds against AChE (IC50 0.33 nM in the best case, 44-fold increased potency over 6-chlorotacrine), butyrylcholinesterase (IC50 21 nM in the best case, 24-fold increased potency over 6-chlorotacrine), and NMDA receptors (IC50 0.89 µM in the best case, 2-fold increased potency over the parent benzohomoadamantanamine and memantine), which suggests an additive effect of both pharmacophoric moieties in the interaction with the primary targets. Moreover, most of these compounds have been predicted to be brain permeable. This set of biological properties makes them promising leads for further anti-Alzheimer drug development.

Subject

Malaltia d'Alzheimer, Malalties neurodegeneratives, Escorça cerebral, Química farmacèutica

Subject (English)

Alzheimer's disease, Neurodegenerative Diseases, Cerebral cortex, Pharmaceutical chemistry

Citation

Collections

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Citation

PÉREZ AREALES, Francisco Javier, et al. A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. European Journal of Medicinal Chemistry. 2019. ISSN 0223-5234. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/141878

Export metadata

JSON - METS

Share record